Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer.

clinical disease state and effect of treatment. J Immunol 2001; 167: 5217–5225. 3 Carrara S, Vincenti D, Petrosillo N, et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004; 38: 754–756. 4 Kobashi Y, Mouri K, Fukuda M, et al. Transitional change in the clinical features of pulmonary tuberculosis. Respiration 2008; 75: 304–309. 5 Bosshard V, Roux-Lombard P, Perneger T, et al. Do results of the T-SPOT.TB interferon-c release assay change after treatment of tuberculosis? Respir Med 2009; 103: 30–34. 6 Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956–973. 7 Wu-Hsieh BA, Chen CK, Chang JH, et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 2001; 33: 1336–1340. 8 Ribeiro S, Dooley K, Hackman J, et al. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis 2009; 9: 23. 9 Dheda K, Pooran A, Pai M, et al. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-c release assays (T-SPOT.TB) and factors that may modulate test results. J Infect 2007; 55: 169–173. 10 Elias D, Britton S, Kassu A, et al. Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance. Expert Rev Anti Infect Ther 2007; 5: 475–484.